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Abstract  
Objective 
Central nervous system (CNS) features in children with permanent neonatal diabetes 
(PNDM) due to KCNJ11 mutations have a major impact on affected families.  Sulfonylurea 
therapy achieves outstanding metabolic control, but only partial improvement in CNS 
features.  The effects of KCNJ11 mutations on the adult brain and their functional impact are 
not well described.  We aimed to characterise the CNS features in adults with KCNJ11 
PNDM, compared to adults with INS PNDM.   
Research Design and Methods 
Adults with PNDM due to KCNJ11 mutations (n=8) or INS mutations (n=4) underwent a 
neurological examination, and completed standardised neuropsychological 
tests/questionnaires about development/behavior.  Four individuals in each group underwent 
a brain MRI scan.  Test scores were converted to Z-scores using normative data, and 
outcomes compared between groups.   
Results 
In individuals with KCNJ11 mutations, neurological examination was abnormal in 7/8; 
predominant features were subtle deficits in coordination/motor sequencing. All had delayed 
developmental milestones and/or required learning support/special schooling.  Half had 
features and/or a clinical diagnosis of autism spectrum disorder.  KCNJ11 mutations were 
also associated with impaired attention, working memory and perceptual reasoning, and 
reduced IQ (median IQ KCNJ11 vs INS mutations 76 vs 111, p=0.02).  However, no 
structural brain abnormalities were noted on MRI. The severity of these features was related 
to the specific mutation and they were absent in individuals with INS mutations.   
Conclusions 
KCNJ11 PNDM is associated with specific CNS features which are not due to long-standing 
diabetes, persist into adulthood despite sulfonylurea therapy, and represent the major burden 
from KCNJ11 mutations.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
KCNJ11 gene mutations are the commonest cause of permanent neonatal diabetes (PNDM), 
which presents in the first 6 months of life and affects 1 in 100,000 live births (1).  KCNJ11 
is expressed in the pancreas and brain as well as other tissues, and encodes the Kir6.2 subunit 
of the ATP-dependent potassium (KATP) channel.  In the pancreas, the KATP channel links 
increasing blood glucose to insulin secretion, but activating KCNJ11 mutations prevent 
channel closure in response to metabolically generated ATP and result in diabetes (2).  
Clinically, patients present in an insulin-deficient state and prior to discovery of disease-
causing variants in the KCNJ11 gene they required insulin therapy.   It was later shown that 
KCNJ11 PNDM could be treated with sulfonylurea tablets, which bind and close the channel 
allowing insulin secretion, excellent metabolic control and reduced glycaemic variability (3).  
For many patients and their families transferring from insulin to oral sulfonylureas vastly 
improved quality of life in relation to their diabetes (4).   
 
Central nervous system (CNS) features occur in children with KCNJ11 PNDM in addition to 
diabetes. These are thought to result from expression of aberrant KATP channels in the brain. 
The precise role(s) of KATP channels in the human CNS has not been fully elucidated, but 
rodent studies suggest that they play a role in glucose sensing and homeostasis as well as 
seizure propagation (5; 6). KCNJ11 is expressed in many brain areas but there are particularly 
high levels of expression in the cerebellum (7; 8). The cerebellum is well known for its role 
in motor learning and coordination (9), but it also has functions relating to language, 
executive function and to mood; furthermore, cerebellar abnormalities have been linked with 
autism (10; 11).  Documented CNS features in children with KCNJ11 mutations range from 
subtle neuropsychological impairments that specifically affect attention, praxis and executive 
function to the severe and overt DEND/intermediate DEND syndrome (developmental delay, 
epilepsy and neonatal diabetes) (12-15).  Other associated features may include psychiatric 
morbidity, specifically neurodevelopmental disorders and anxiety disorders, visuomotor 
impairments, and sleep disturbance (16-18).  The severity of the CNS phenotype is related to 
the genotype.  For example, the V59M mutation is frequently associated with iDEND 
syndrome and neurodevelopmental features whereas the R201H mutation, previously 
associated with diabetes alone, has been more recently linked with subtle neuropsychological 
features (12).  Historically, the severity of CNS features was thought to be related to the 
functional severity of the specific mutation in vitro, although functional interpretation also 
has to take into account the impact of the mutation on the open probability of the KATP 
channel which will depend on whether it affects channel gating or ATP binding (19-22). 
 
Sulfonylurea treatment results in partial improvement in the CNS features (23-26), and 
resolution of functional cerebellar and temporal lobe abnormalities on single-photon emission 
computed tomography (SPECT) scanning (24; 27).   The improvement in CNS features may 
be limited as a result of poor penetration of the sulfonylurea across the blood brain barrier or 
active transport back out of the brain, leading to sub-therapeutic concentrations in the 
cerebrospinal fluid (CSF) (28).  This, and anecdotal clinical experience of greater CNS 
response with higher doses of sulfonylurea, has prompted clinical recommendations of 
glyburide doses of ~1mg/kg/day in people with severe neurological features secondary to 
KCNJ11 mutations (29).  However, the neurobehavioral features continue to have a huge 
impact on families despite sulfonylurea treatment (16).  This contrasts markedly with the 
outstanding metabolic response that changed lives by alleviating the anxiety associated with 
poor metabolic control (4).  A key question is whether the CNS features continue to represent 
the major burden from KCNJ11 mutations in adult life.  To date all studies characterising 
CNS features in KCNJ11 PNDM have been conducted in predominantly paediatric cohorts 
(12-14; 16; 23).  However, brain development continues beyond childhood and adolescence 
(30; 31).  No study has comprehensively assessed the CNS outcomes in adults with KCNJ11 
mutations.   
 
Mutations in the INS gene are a less common cause of neonatal diabetes, accounting for 
around 10% of cases (1).  Heterozygous dominant negative INS mutations often affect protein 
synthesis resulting in production of structurally abnormal preproinsulin and proinsulin within 
the beta cell, endoplasmic reticulum (ER) stress and cell death.  Individuals with these 
mutations also typically present with insulin deficiency, but unlike KCNJ11 PNDM, require 
lifelong treatment with replacement doses of insulin (32).  The INS gene is not expressed in 
any significant levels in the brain, therefore it is very unlikely that individuals with INS 
mutations would display a characteristic CNS phenotype as a direct result of their mutations 
(33).  In fact, there have not been any reports of any such neurological issues, in contrast to 
those with KCNJ11 PNDM. 
 
Individuals with PNDM may have long-term CNS sequelae secondary to diabetic 
ketoacidosis at diagnosis, as seen in Type 1 diabetes (34; 35).  However, cerebral oedema in 
KCNJ11 PNDM gives rise to a pattern of neurological impairment distinct from that seen as a 
direct result of brain KATP channel dysfunction (36).  More subtle neurocognitive problems 
also occur in the presence of diabetes per se, particularly if metabolic control is poor and 
diabetes is diagnosed before age 7 (37).  Further, individuals with Type 2 diabetes are at 
increased risk of developing Alzheimer’s disease in later life, and this may be in part due to 
chronic metabolic disturbance and changes in insulin signalling (38).  Indeed, there is 
evidence from both animal and human studies that insulin plays a key role in central 
processes including memory and learning (38).  The non-specific diabetes-related cognitive 
features could confound assessment of CNS phenotype in people with KCNJ11 mutations, 
however people with INS mutations are well placed to control for them.  There has been no 
previous detailed comparison of the CNS phenotype in people with INS and KCNJ11 
mutations. 
 
Aims 
The aims of the study were to characterise the neurological and neuropsychological features 
in adults with KCNJ11 PNDM, and to compare these with adults with INS PNDM.   
 
Methods 
Ethical approval 
Ethical approval was obtained from the National Research Ethics Service Committee South 
West-Exeter. 
 
Sample size and patient recruitment 
We identified 34 patients >16 years old with KCNJ11 mutations and 9 patients >16 years old 
with INS mutations who had received a molecular genetic diagnosis in Exeter and who had 
been diagnosed with permanent neonatal diabetes under 6 months of age. We approached 
potential participants either directly at a neonatal diabetes family event in Exeter or via the 
Consultants in charge of their clinical care. We invited 17 individuals with KCNJ11 
mutations to join the study; of these, 10 agreed to participate.  However, 2 individuals were 
excluded from the analysis due to possible confounding factors: one individual (mutation 
L164P) was excluded because he was taking antipsychotic medication to treat a psychotic 
illness at the time of the study and had had a particularly severe initial presentation with 
diabetic ketoacidosis and 3 days in a coma, and a second individual (mutation V59M) was 
excluded due to severe neurological impairment following initial presentation with diabetic 
ketoacidosis (further clinical characteristics of excluded participants are available in online 
supplemental Table S1).  We approached 9 individuals with INS mutations and 4 agreed to 
take part.  All participants were from the UK apart from one who was from Canada. 
 
Tests 
All participants were visited at home or assessed in the Exeter Clinical Research Facility by 
the same Consultant neurologist and Consultant clinical neuropsychologist who carried out 
the history taking using a standard proforma, neurological examination, neuropsychological 
assessments, mood questionnaire and neurodevelopmental screen.  If possible an informant or 
carer was also present to facilitate information gathering.  The severity of intellectual 
impairment and behavioral disturbance in one individual (KCNJ11-8 [V59M]) meant that it 
was not possible for him to attempt any of the cognitive tests.  Another individual (KCNJ11-6 
[V252G]) did not wish to attempt the Controlled Oral Word Association Test (COWAT) and 
was unable to understand instructions for the Colour Trails Test (CTT).  In 8 participants (4 
with KCNJ11 mutations and 4 with INS mutations), T2-weighted brain magnetic resonance 
imaging (MRI) scans were performed using a 1.5T MRI scanner.  The scans were reviewed 
and interpreted by a radiologist and a neurologist who were blinded to the mutation status of 
the individuals concerned. 
 
Medical / developmental history, educational and professional attainment 
Participants and informants were asked for a standard medical history, the ages at which 
major milestones were attained, whether learning support was required and level of education 
/ employment. 
 
Neurological Examination 
A full neurological examination was performed.  This included assessment of cranial nerves, 
limb tone, power, reflexes, coordination, sensation, and simple tests of motor sequencing and 
praxis, comprising 2 tests of bimanual coordination, one unilateral motor sequencing task (the 
Luria three hand position test), copying unfamiliar hand positions and manual miming, both 
tested in each hand.  
 
Psychiatric and neurodevelopmental screen 
Current psychological distress was assessed using the Hospital Anxiety and Depression Scale 
(HADS) questionnaire.  The Autism Spectrum Quotient (AQ) was administered to screen for 
autistic traits. 
 
Cognitive function 
A battery of neuropsychological tests were administered to assess a variety of cognitive 
domains.  The Wechsler Abbreviated Scale of Intelligence (WASI) was used as a brief 
measure of current IQ.  The Verbal Paired Associates and Visual Reproduction subtests of 
the Wechsler Memory Scale (WMS-IV) were used to give a verbal and non-verbal (visual) 
measure of memory.  Subtests of the Wechsler Adult Intelligence Scale, 4th edition (WAIS-
IV) were administered: cancellation to assess processing speed and digit span (forwards and 
backwards) to assess working memory.  Subtests of the Visual Object and Space Perception 
battery (VOSP) assessed visuospatial function; incomplete letters and object decision to test 
object perception, and dot counting and cube analysis to test spatial perception.   The 
Controlled Oral Word Association Test (COWAT) was used to assess aspects of executive 
function including verbal fluency, self-monitoring and ability to assimilate and adhere to 
stipulated rules.  The Colour Trails Test (CTT) 1 and 2 were used as measures of sustained 
and divided attention, hand eye motor coordination and speed.  Finally, the Addenbrooke’s 
Cognitive Examination-Revised (ACE-R) was used as a broad screening measure of 
cognition, providing an assessment of the following cognitive domains; attention/orientation, 
memory, fluency, language, and visuospatial function.  
 
Functional assessment  
The Cambridge Behavioral Inventory Revised (CBI-R) questionnaire was used to 
complement the information obtained from the history taking. This measure seeks the opinion 
of the informant e.g. carer or family member on the frequency of a range of behaviors in the 
domains of memory and orientation, everyday skills, self-care, abnormal behavior (e.g. 
tactlessness, impulsiveness), mood, unusual beliefs, altered eating habits, disturbed sleep, 
stereotypic and motor behaviors, and altered motivation.  For each behavior the informant 
assigned a score of 0-4 based on the frequency: scores of 3 (occurring daily) or 4 (occurring 
constantly) denote a significant behavioral deficit. 
 
Statistical analysis 
Data were analysed using Excel 2010 and Stata 14.  Qualitative data were presented 
descriptively.  Where population normative data were available, neuropsychological test 
scores were converted to Z-scores.  For VOSP subtests, a pass was a score ≥5th population 
percentile.  To compare characteristics and outcomes between the KCNJ11 and INS groups, 
data were analysed using non-parametric methods (Mann-Whitney test for numerical 
variables and Fisher’s exact test for categorical variables).  Data are presented as median 
(range) unless otherwise stated.  
 
 
Results 
Participant Characteristics 
Baseline clinical characteristics of the participants are outlined in Table 1; these were similar 
between individuals with KCNJ11 mutations and individuals with INS mutations. 
 
Neurological Features 
Abnormalities on neurological examination were identified in 7/8 KCNJ11 participants and 
only one INS participant (Table 2).   
 
Developmental History, Educational and Professional Attainment 
Developmental histories, level of educational support and employment history reported for 
each participant are described in Table 2.  Developmental delay and / or learning difficulties 
were present in all KCNJ11 participants and they continued to require high levels of support 
as adults.  In contrast, the INS group did not report major learning difficulties in keeping with 
their subsequent employment history and independence in adulthood.  
 
Neurodevelopmental and Psychiatric Features  
4/8 with KCNJ11 mutations, but none of the participants with INS mutations, had features of 
autistic spectrum disorder, either via a clinical diagnosis of autism or an AQ score at or above 
the threshold suggestive of clinically significant autistic traits (Table 2 and S3).  Two 
individuals in the KCNJ11 group and one in the INS group required treatment either at the 
time of the study or in the past for depression or anxiety.  HADS scores for anxiety and 
depression were similar in KCNJ11 vs INS participants (Table S3).  One individual in the 
KCNJ11 group and 2 individuals in the INS group scored above the HADS clinical threshold 
(11) for anxiety (Table 2, Table S3).   
 Cognitive Function  
IQ was lower in the KCNJ11 group vs the INS group (IQ 76(55-101), n=7 and 111(90-124), 
n=4, p=0.02).  Three individuals in the KCNJ11 group had IQs <70 (Table S2) and 
impairments in adaptive behaviors in-keeping with a clinical diagnosis of intellectual 
disability (39). 5/7 individuals in the KCNJ11 group scored below the clinical cut-point for 
cognitive impairment on the ACE-R (Figure S1). CTT1 scores suggested reduced attention 
(CTT1 Z-score -1.7(-3.0- -0.1), n=6 vs 0.4(-1.1-1.2), n=4, p=0.03, CTT2 Z-score -0.8(-3.0-
0.8), n=6 vs. 0.7(-1.0-1.2), n=4, p=0.13 (Figure 2, Table S2)). 
 
In the KCNJ11 group but not the INS group median scores in the WASI, WAIS and WMS were 
below population average in all subtests apart from the verbal paired associates subtest of the 
WMS (Figure 1).  Scores were particularly low (≤2SD below population average) in the 
matrix reasoning component of the WASI (Z-score -3.2(-4.8- -0.9) vs. 0.6(-0.7-0.8), p=0.008) 
and the digit span component of the WAIS-IV (Z-score -2.0(-3.0-0.3) vs 0(-1.0-0.3), 
p=0.046).  Cancellation scores, although not as markedly reduced compared to population 
norms, were significantly lower in the KCNJ11 group (Z-score -1(-3-0) vs 2.8(0.7-3.0), 
p=0.007).  COWAT and VOSP scores showed a trend towards reduced executive function 
and visuospatial function respectively in the KCNJ11 group (Table S3), although these did 
not reach statistical significance.   
 
Behavioral / functional impact 
In the KCNJ11 group, 6 individuals had severe behavioral features which clustered in the 
domains of everyday skills (5/6), stereotypic behavior (5/6), memory and orientation (4/6), 
abnormal behavior (3/6), mood (3/6), and motivation (3/6).  Specific everyday skills 
highlighted included writing (3/5) and dealing with money/bills (2/5).  The most frequent 
stereotypic behaviors were being rigid / fixed (3/5) and having fixed routines (4/5).  Poor 
concentration was highlighted as a specific feature in all 4 individuals who had memory and 
orientation problems.  Two individuals had significant difficulties with self-care and 2 
reported disturbed sleep.  
 
Neuroimaging 
Structural brain MRI was normal in participants with KCNJ11 mutations.  In INS controls, 2 
were normal, and 2 had minor abnormalities which were not clinically significant (Table 2).  
 
Severity of impairments associated with the specific mutation 
Performance in the cognitive tests was better in the 2 individuals with the R201H mutation.  
These individuals consistently had scores equal to or greater than the KCNJ11 group medians 
(Figures 1 and 2, Table S2), and no significant behavioral features were reported.  
 
Discussion 
We have characterised for the first time the profile of neurological, neuropsychological and 
behavioral features present in adults with PNDM due to KCNJ11 mutations.  The key 
features were learning difficulties, features of ASD, subtle motor deficits affecting 
coordination and motor sequencing, and reduced IQ.  Specific cognitive domains most 
affected were perceptual/non-verbal reasoning, working memory, and attention, with a trend 
towards executive dysfunction and impaired visuospatial abilities.  Verbal paired associate 
memory was relatively preserved.  The impact on everyday functioning was significant; 2 
participants were severely impaired, requiring support with activities of daily living.  A 
comparison group of patients with neonatal diabetes of similar duration due to INS mutations 
did not show any of these specific features indicating that they are unlikely to be a non-
specific effect of metabolic disturbance from birth.  Furthermore, as both groups were insulin 
treated from diagnosis as infants, the differences observed are unlikely to have been 
influenced by variation in the timing or duration of action of insulin on insulin and IGF 
receptors in the brain.   
 
Our findings are consistent with studies in paediatric cohorts with KCNJ11 neonatal diabetes.  
Specifically, the motor features noted on neurological examination, together with 
impairments of attention, working memory, visuospatial ability and executive function are 
consistent with the previously reported high prevalence of developmental coordination 
disorder, inattention, executive dysfunction and poor visuomotor performance in children 
with KCNJ11 mutations (12-14; 17; 18; 23; 40).  ASD features in 4 individuals with KCNJ11 
mutations is consistent with previous research reporting high rates of neurodevelopmental 
disorders in affected children (16; 18; 41).  Dyspraxia, visuomotor impairment, autism and 
impaired executive function may be related to the high levels of expression of dysfunctional 
KATP channels in the cerebellum in KCNJ11 PNDM (7; 10).   
 
Importantly, the abnormal findings we report in the KCNJ11 group were mutation-specific; 
the 2 individuals with the R201H mutation had no overt features and only some subtle 
abnormalities on neuropsychological testing (Table S2).  As a result, both were able to live 
independently and support themselves financially.  Those with more severe features required 
high levels of support from family members and professionals in healthcare, education and 
social care.  This is consistent with previous studies showing the severity of the CNS 
phenotype is related to the  specific mutation; for example, the V59M mutation results in 
more severe features, greater impairment in daily living skills (13) and greater impact on 
families (16).  Interestingly, however, there was a relatively good level of social integration 
from all patients with KCNJ11 mutations even when the neurobehavioral features were 
severe. 
 
Some of our findings contrast with previous research.  To our knowledge choreiform 
movements have not been previously associated with KCNJ11 PNDM but were observed in 
one individual with the V59M mutation in our study.  We did not identify abnormal tone in 
our cohort, which contrasts with the hypotonia previously reported, particularly in the context 
of DEND/iDEND syndrome (42).  This may be explained by 7/8 individuals in our study 
being sulfonylurea-treated; improvement in tone to near-normal following transfer from 
insulin to sulfonylureas has been observed in a recent study of children with KCNJ11 PNDM 
(23).  Similarly, improvement of visuospatial abilities and attention following transfer to 
sulfonylureas was noted in the paediatric study (23), which could account for the attention 
deficits and visuospatial impairment being less marked in our cohort of sulfonylurea-treated 
adults than might have been expected given previous descriptions (17; 23).  Our 
neuroimaging findings contrast with this paediatric study in which there were non-specific 
findings in 12/17 who underwent brain MRI, largely comprising white matter abnormalities 
(23).  However, these scans were performed at baseline prior to transfer to sulfonylureas (23).  
It is not known whether the abnormalities would have improved after a period of sulfonylurea 
treatment, as has been shown in SPECT studies (24; 27).  
 
Sulfonylurea treatment may influence the CNS phenotype in KCNJ11 PNDM.  Two studies 
have suggested that an earlier age of initiation of sulfonylureas can lead to better CNS 
outcomes (17; 23).  We were unable to assess this in our study because median age at transfer 
to sulfonylureas was 18 years (range 11-34).  However, the persistence of CNS features in 
some patients even after early initiation of treatment (16; 23) suggests other factors are 
involved.  Specifically, active transport of glyburide out of the brain across the blood-brain 
barrier, as has been demonstrated in a rodent model (28), may result in suboptimal 
concentrations in the CSF, thereby limiting therapeutic efficacy in the human CNS.  
Anecdotal clinical experience suggests that this can be partially addressed by increasing the 
dose of glyburide to ~1mg/kg/day; however there have been no cases of complete resolution 
of CNS features in a patient with iDEND.  Another possible reason for the partial response is 
that pathways that can fully restore KATP channel function in other tissues are not available in 
the CNS to interact with brain KATP channels.  For example, restoration of pancreatic KATP 
channel function resulting in excellent glycaemic control with sulfonylurea treatment is 
dependent on the activity of incretin hormones (3).  Furthermore, there is a theoretical impact 
of insulin deficiency in utero and / or C-peptide deficiency prior to sulfonylurea transfer on 
the brain as an indirect consequence of KCNJ11 mutations, but more studies are needed to 
explore this in humans.  Indeed, given the complexities of human neurodevelopmental 
processes, it is likely that several factors contribute in some way to the response of CNS 
features to sulfonylureas in KCNJ11 PNDM.   
 
Strengths, Limitations and future work 
This study has important strengths.  It is the first to assess in detail the CNS manifestations of 
KCNJ11 mutations in adults and to control for the non-specific effects of PNDM by 
comparing the features in individuals with INS mutations.  Limitations of the study, which 
relate to the rarity of the disease, are the small number of individuals in each group, the broad 
range of mutations studied, and the variable timing of initiation and duration of treatment 
with sulfonylureas in the KCNJ11 group.  Studies in larger cohorts with single specific 
mutations would be valuable.  Furthermore, exploration of the impact of treatment-specific 
factors, such as age of initiation, dose and CNS handling of sulfonylureas in humans, on CNS 
features in KCNJ11 PNDM is warranted.   
 
Conclusion 
The CNS phenotype in adults with KCNJ11 mutations comprises learning difficulty, autistic 
features, subtle motor dysfunction, moderately reduced IQ, and impaired attention, perceptual 
reasoning and working memory.  The severity of these features varies with the causative 
mutation. They persist despite long term sulfonylurea therapy, at least when this is started 
after the first decade of life, and represent the major burden from KCNJ11 mutations once 
glycemia is well controlled on sulfonylureas.  These CNS features are not present in 
individuals with INS mutations, which indicates that they do not occur as a result of the 
lifelong metabolic disturbance imposed by PNDM, but as a consequence of impaired KATP 
channel function in the brain.  Clinicians in adult and paediatric medicine should be aware of 
the potential impact of CNS features in patients with KCNJ11 mutations and should consider 
multidisciplinary management to ensure appropriate support is provided.   
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Figure legends 
Figure 1: Neuropsychological testing in KCNJ11 patients (blue, n=7) and INS patients 
(orange, n=4).  WMS: Verbal paired associates I/II (immediate/delayed) – auditory memory, 
Visual reproduction I/II (immediate/delayed) – visual memory (both components of working 
memory) WASI: Vocabulary - word knowledge and verbal concept formation, matrix 
reasoning – non-verbal/perceptual reasoning.  Digit span – working memory, cancellation – 
processing speed. *denotes p<0.05 for difference between KCNJ11 and INS groups. 
  
Figure 2: Colour Trails Test 1&2 scores represented as Z-scores in the KCNJ11 group (blue, 
n=6) and INS group (orange, n=4).  Lines show group medians for each subtest; dots 
represent individuals. *denotes p<0.05 for difference between KCNJ11 and INS groups. 
 
Figure S1; ACE-R in KCNJ11 individuals (blue), n=7 and INS individuals (orange), n=4.  
Scores are presented as percentages of maximum possible score for each subsection.  A total 
score of ≤82 is suggests clinically relevant cognitive impairment.
 TABLE 1 - Baseline characteristics in individual participants KCNJ11 cases and INS controls and group characteristics summary.   
 
 
Summary numerical data are presented as median (range) and categorical variables are presented as n (%).  Mutations were presumed to have arisen de novo if there was no parental history of 
diabetes but the mutation status of the parents had not been confirmed with a genetic test.  HbA1c values are the results available closest to the time of the neurobehavioral assessment. N/A = 
not applicable, NK = not known. 
Case  Mutation Inheritance Sex Age Age at diabetes 
diagnosis 
(weeks) 
Age at genetic 
diagnosis 
(years) 
Age at 
transfer to 
SU (years) 
Treatment (total daily dose) HbA1c 
DCCT (%) 
HbA1c 
IFCC 
(mmol/mol) 
KCNJ11 1 G53S Autosomal 
dominant 
M 32 2 23 23 Glyburide 30mg, metformin 1g  9.3 78 
KCNJ11 2 R201H Presumed de 
novo 
F 22 4  15 15 (attempted) Insulin (restarted after trial of glyburide) 8.1 65 
KCNJ11 3 R201H De novo M 36 10  29 29 Gliclazide (120mg) 8.1 65 
KCNJ11 4 R201C Presumed de 
novo 
F 36 5  27 34 Glyburide (40mg) 7.0 53 
KCNJ11 5 R201C De novo M 19 6  13 13 Glyburide 27.5mg  5.4 36 
KCNJ11 6 V252G De novo M 28 8 21 21 Glyburide (85mg)  10.8 95 
KCNJ11 7 V59M De novo F 25 15  17 17 Glyburide (7.5mg) 8.1 65 
KCNJ11 8 V59M De novo M 17 5 10 11 Glyburide (55mg) 5.9 41 
INS 1 C43F Autosomal 
dominant 
F 35 78 31 N/A Insulin  NK NK 
INS 2 F48C Presumed de 
novo 
F 50 5 42 N/A Insulin NK NK 
INS 3 G75C De novo M 28 8 26 N/A Insulin 7.9 63 
INS 4 H29D De novo F 20 26 12 N/A Insulin (pump)   8.2 66 
    
KCNJ11 
group 
N/A De novo = 7 
(87.5%) 
Autosomal 
dominant = 
1 (12.5%) 
M = 5 
(63%) 
F = 3 
(37%) 
26.5 
(17-
36) 
5.5 (2-15) 19 (10-29) 21 (11-34) Insulin treated = 1/8 8.1 (5.4-
10.8) 
65 (36-95) 
INS group N/A De novo = 3 
(75%) 
Autosomal 
dominant = 
1 (25%) 
M = 1 
(25%) 
F = 3 
(75%) 
31.5 
(20-
50) 
17 (5-78) 28.5 (12-42) N/A Insulin treated = 4/4 8.1 (7.9-8.2) 65 (63-66) 
P value N/A 1.0 0.55 0.44 0.15 0.23 N/A 0.01 0.79 0.79 
TABLE 2 - History and examination findings for individual KCNJ11 cases and INS controls.   
NK = not known, ND = not done, D=delayed, N=normal, MS = Mainstream school, SS = Special school, U = University, C = College, LS = learning support, E = employed, UE = 
unemployed, ID = intellectual disability, US = university student, CS = college student, OCD = obsessive compulsive disorder, DKA = diabetic ketoacidosis, F = father, M = mother, B = 
brother, S = sister 
Case 
(mutation)  
HISTORY EXAMINATION / INVESTIGATIONS 
Developmental 
milestones / 
interventions 
Seizures 
(cause, if 
known) 
Educational 
attainment  
Learning 
difficulties / 
support 
Employment 
status (job) 
Employment status (job) 
of parents / siblings 
Psychiatric history  Neurological examination Brain MRI 
KCNJ11 1 
(G53S) 
D (speech and 
motor)  
No  MS then SS 
(age 11) 
LS (repeated 
year 2) 
E (supermarket) F – E (council), S – E 
(chemicals factory) 
Repetitive hand 
washing and rigid 
routines.  
Impaired motor sequencing, 
fine finger movements, 
praxis. Subtle nystagmus, 
dysdiadokokinesis. 
ND 
KCNJ11 2 
(R201H) 
D (speech) No MS then U 
(nursing and 
childcare)  
LS (English 
until age 15, 
Maths for 1 
year) 
US F – E (accountant) M – E 
(nurse) 
Nil Intermittent mild head 
titubation. Brisk reflexes, 
questionable increase in tone 
in left arm.   
N 
KCNJ11 3 
(R201H) 
N Yes – 
hypoglyca
emia on 
insulin 
MS then C 
(18 months, 
NVQs levels 
1 &2) 
LS (English and 
Maths).  
E (baker) NK Nil Normal Bilateral high T1 
signal in pons – 
artefact 
KCNJ11 4 
(R201C) 
N Yes  MS then C 
(computing 
module) 
LS (throughout 
school) 
E (pubs, shops, 
hotel) 
B – E (operations manager), 
S – E (sports complex 
manager) 
Depression – 
Sertraline 50mg. 
Occasional auditory 
hallucinations. 
Nystagmus (2-3 beats on 
horizontal gaze), subtle 
intention tremor. 
N 
KCNJ11 5 
(R201C) 
D (gross motor, 
speech).Speech 
therapy. 
Yes –
hypoglyca
emia on 
insulin 
MS then C 
(for people 
with ID) 
LS (from age 
10).   
CS (college for 
people with ID). 
F – E (company manager), 
M - UE (housewife), B – E 
(aviation engineer), B – US 
(political science) 
Anxiety (social skills 
training by 
psychologist)  
Impaired motor sequencing. ND 
KCNJ11 6 
(V252G) 
D (speech, fine 
motor). Speech 
therapy. 
No SS then 
school for 
autistic 
children  
Unable to 
read/write. 
Supported 
accommodation. 
UE B – E (carpenter) Autism Impaired motor sequencing, 
praxis, heel-toe walking. 
Hand-flapping. 
ND 
KCNJ11 7 
(V59M) 
Speech therapy.  Yes – 
hypoglyca
emia on 
insulin 
MS then C (1st  
year - 
childcare)  
LS (throughout 
school) 
E (SS teaching 
assistant) 
M – E (SS teaching 
assistant), F – E (lecturer), 
B – E (trainee lawyer) 
Anxiety Impaired motor sequencing, 
dysdiadokokinesis, 
choreiform movements. 
N (movement 
artefact) 
KCNJ11 8 
(V59M) 
D (global).  Yes – 
hypoglyca
emia on 
insulin 
SS Unable to 
read/write. 
UE S – E (museum curator) Autism Ritualistic, clumsy, echolalia.  
Generally uncooperative with 
examination. 
ND 
INS 1 (C43F) N Yes  U (pharmacy 
degree)  
No E (hospital 
pharmacist)  
NK Nil Normal ND 
INS 2 (F48C) N Yes –
hypoglyca
emia 
U (law 
degree) 
No support.  UE (ill health). 
Clerical / carer 
jobs in past 
F – E (taxi business 
manager, security guard) 
Depression 
(medication and CBT 
in the past), OCD 
Depressed leg reflexes (in-
keeping with known diabetic 
neuropathy).   
Left temporal lobe 
abnormality – CSF 
space or artefact 
INS 3 (G75C) N No  MS  No support.  E (dept. of work 
and pensions) 
F – E (carpenter, transport 
manager), B – E (marketing 
agency) 
Nil N N 
INS 4 (H29D) N Yes – 
DKA 
MS LS (Maths & 
English 4 
years). 
E (bank call 
centre)  
F – E (carpenter) Anxiety, panic attacks 
(Escitalopram in the 
past) 
N Prominent left 
cerebellar sulcus, 
periventricular white 
matter lesions  
